We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Clear all

Refine your search

Content type


Firm name


395 results found


Bristows | USA, European Union | 3 Jun 2019

CLIP of the month: FTC’s latest report on patent settlement agreements and the question of “possible compensation”

Like the European Commission, the US FTC requires agreements settling pharmaceutical patent disputes to be lodged with it. Last week it published its


Rothwell, Figg, Ernst & Manbeck, PC | USA, European Union | 7 May 2019

How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline

FDA approves the second Enbrel (etanercept) biosimilarno etanercept biosimilar has launched in the United States to date. FDA approves the fourth


Mintz | USA | 29 Apr 2019

FTC Alleges Surescripts Illegally Monopolized E-Prescription Market

The Federal Trade Commission (“FTC” or “Commission”) has added to its growing list of recent enforcement actions against health care companies, all of


Hall Render Killian Heath & Lyman PC | USA | 19 Apr 2019

340B Moving Forward: Legislative and Executive Branch 340B Priorities for 2019-2020

We continue to receive questions regarding the future of the 340B Drug Discount Program (“340B Program”) now that its mid-term longevity is no longer


Paul Hastings LLP | USA | 11 Apr 2019

Not a U.S.-Fits-All-Proposition: Four Key Considerations When Building the Compliance Framework to Go Global with Patient SupportPart I of II

Within the U.S., patient support programs (“PSPs”) have drawn increased regulator scrutiny, consistent with their growing importance in the healthcare


Baker & Hostetler LLP | USA | 8 Apr 2019

Capitol Hill Healthcare Update

Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session


IAM | USA, European Union | 6 Apr 2019

The big biopharma patent developments in March

Major court decisions in Europe and the US, a boost for Bristol Meyers’ proposed purchase of Celgene, another AbbeVie Humira suit, a CRISPR grant for


Bereskin & Parr LLP | Canada | 26 Mar 2019

Double Trouble: Avoiding Pitfalls in Canadian Pharmaceutical Patent Practice

Over the past several years, the environment for pharmaceutical patents in Canada has improved significantly. As was widely reported at the time, the


Drinker Biddle & Reath LLP | USA | 21 Mar 2019

Reliance Remains a High Hurdle in Establishing Third-Party Payor Claims

Third-party payor (TPP) claims against pharmaceutical companies are nothing new. The arguments are common - TPP insurers claim financial injury


McKee Voorhees & Sease PLC | USA | 12 Mar 2019

How Many Patents Are Enough for a Product?

The answer to the question of course, depends on the commercial value of the product. However, it is also obvious that the commercial value of a

Previous page 1 2 3 ...